Merck

Merck & Co., Inc. is a research-intensive biopharmaceutical company focused on developing health solutions to help prevent and treat diseases in people and animals. Its ophthalmology research is centered on therapies intended to protect, restore and improve vision, with a particular focus on retinal diseases that have significant unmet medical needs.

Through its subsidiary Eyebiotech Limited (EyeBio), Merck is advancing a pipeline of potential treatments for conditions including diabetic macular edema and neovascular age-related macular degeneration, also known as wet AMD. These diseases can damage central vision and may cause severe vision loss if untreated. Merck and EyeBio scientists are investigating biological targets, including the Wnt signaling pathway, to address vascular leakage and support the integrity of the blood-retinal barrier.

The company presents these efforts as research and development rather than established treatment services, and notes that pipeline candidates may not receive regulatory approval. Beyond ophthalmology, Merck conducts research across areas such as oncology, vaccines, infectious diseases, immunology and neuroscience, and provides patient support programs, clinical-trial information and access resources for eligible patients